BioStock: PHI aims for US listing
Swedish Medtech Phase Holographic Imaging is making significant strides in the United States, establishing itself at the forefront of the rapidly growing regenerative medicine field. PHI is now taking an important step by applying for listing its shares in the US OTCQB market to enhance its presence and opportunities in the US. BioStock talked to CEO Patrik Eschricht to learn more about what this means for the company.
Read the full interview with Patrik Eschricht on biostock.se.
We are very happy about the possibility of dual-listing on the OTCQB, which would be another significant step in PHI’s growth journey as a global company. This dual listing would make it more accessible for international investors to invest in PHI, positively increasing liquidity, boosting shareholder value, and supporting our ongoing growth.
Further reading
BioStock: PHI “We aim to revolutionize the regenerative medicine market“
BioStock: PHI’s CEO reflects on the Company’s momentum
BioStock: Altium fuels PHI’s forward drive
